Skip to main navigation Skip to search Skip to main content

Long-Term Effects of Radioiodine Treatment on Salivary Gland Function in Adult Survivors of Pediatric Differentiated Thyroid Carcinoma

  • Tharsana Selvakumar
  • , Marloes Nies
  • , Marielle S. Klein Hesselink
  • , Adrienne H. Brouwers
  • , Anouk N. A. van der Horst-Schrivers
  • , Esther N. Klein Hesselink
  • , Wim J. E. Tissing
  • , Arjan Vissink
  • , Thera P. Links*
  • , Gianni Bocca
  • , Johannes G. M. Burgerhof
  • , Eveline W. C. M. van Dam
  • , Bas Havekes
  • , Marry M. van den Heuvel-Eibrink
  • , Eleonora P. M. Corssmit
  • , Leontine C. M. Kremer
  • , Romana T. Netea-Maier
  • , Heleen J. H. van der Pal
  • , Robin P. Peeters
  • , Johannes W. A. Smit
  • John T. M. Plukker, Cecile M. Ronckers, Hanneke M. van Santen, Dutch Pediatric Thyroid Cancer Study Consortium
*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Pediatric differentiated thyroid cancer (DTC) is a rare disease. Initial treatment of DTC consists of a total or near-total thyroidectomy and I-131 therapy. Previous studies on adults showed that I-131 treatment may reduce salivary gland function (SGF). Studies regarding SGF in children treated for DTC are sparse. Our aim was to assess the long-term effects of I-131 treatment on SGF in survivors of pediatric DTC. Methods: In a nationwide cross-sectional study, SGF in patients treated for pediatric DTC between 1970 and 2013 (>5 y after diagnosis, >= 18 y old at the time of evaluation) was studied. SGF was assessed by sialometry, sialochemistry, and a xerostomia inventory. Salivary gland dysfunction (SGD) was defined as an unstimulated whole saliva flow of no more than 0.2 mL/min or a stimulated whole saliva flow of no more than 0.7 mL/min. Results: Sixty-five patients underwent I-131 treatment (median age at evaluation, 33 y, with an interquartile range [IQR] of 25-40 y; 86.2% female; median follow-up period, 11 y, with an IQR of 6-22 y). Median cumulative I-131 activity was 5.88 GBq, with an IQR of 2.92-12.95 GBq, and 47.7% underwent multiple I-131 administrations. SGD was present in 30 (47.6%) patients. Levels of amylase and total protein in saliva were reduced. Moderate to severe xerostomia was present in 22 (35.5%) patients. Stimulated salivary secretion was lower and the severity of xerostomia complaints higher in patients treated with higher cumulative I-131 activity. Conclusion: In survivors of pediatric DTC, clinically significant SGD was found in 35.5% and was related to the cumulative I-131 activity of the treatment.

Original languageEnglish
Pages (from-to)172-177
Number of pages6
JournalJournal of Nuclear Medicine
Volume60
Issue number2
DOIs
Publication statusPublished - 1 Feb 2019

Keywords

  • pediatric differentiated thyroid carcinoma
  • radioiodine treatment
  • salivary gland dysfunction
  • xerostomia
  • RADIOACTIVE IODINE THERAPY
  • QUALITY-OF-LIFE
  • I-131 THERAPY
  • CANCER
  • SIALADENITIS
  • XEROSTOMIA
  • RISK
  • INTERMEDIATE
  • FERTILITY
  • FLOW

Fingerprint

Dive into the research topics of 'Long-Term Effects of Radioiodine Treatment on Salivary Gland Function in Adult Survivors of Pediatric Differentiated Thyroid Carcinoma'. Together they form a unique fingerprint.

Cite this